drugset
drugset / Trial / NCT04093050

Safety and Pharmacokinetics of Vasopressin in Healthy Volunteers

NCT04093050 ↗

Phase 1 Completed 41 enrolled Endo USA Inc., a Keenova Therapeutics Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Open-label Phase I pharmacokinetic (PK) study of Vasostrict® (vasopressin injection, USP) in healthy volunteers.

Timeline

Start
2019-10-10
Primary completion
2021-04-08
Completion
2021-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Vasopressin Peptide — —

Indications

No indication recorded.